GZMB and cancer: Next, we analyzed the release of Granzyme B in the supernatant collected from the 3D-RDL assay, which included the co-cultured hPBMCs together with MKN-45 and DLD-1 cancer spheroids, as well as healthy rectal and intestinal organoid lines, treated at two different doses (10 and 100 nM) of Cibisatamab for 72 h.